Hervé Tilly
Impact in
- Pathology and Forensic Medicine top 0.01%
- Lymphoma Diagnosis and Treatment
- Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research
Papers in
-
- Lymphoma Diagnosis and Treatment 386
- Genetics 155
- Chronic Lymphocytic Leukemia Research 145
- Co-authors
- Bertrand Coiffier (84 shared papers)Gilles Salles (95 shared papers)Éric Lepage (25 shared papers)Christian Gisselbrecht (49 shared papers)Philippe Gaulard (38 shared papers)Corinne Haïoun (115 shared papers)Pierre Lederlin (24 shared papers)Raoul Herbrecht (25 shared papers)
- Journals
- Blood (141 papers)Journal of Clinical Oncology (40 papers)Annals of Oncology (26 papers)Hematological Oncology (23 papers)Leukemia (22 papers)
- Partner nations
- FranceUnited StatesBelgium
In The Last Decade
Hervé Tilly
519 papers receiving 34.6k citations
Hervé Tilly's Hit Papers
Peers
Comparison fields: 5 of 148
- Pathology and Forensic Medicine 24.8k
- Genetics 8.9k
- Oncology 14.7k
- Neurology 5.6k
- Hematology 3.2k
Countries citing papers authored by Hervé Tilly
This map shows the geographic impact of Hervé Tilly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hervé Tilly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hervé Tilly more than expected).
Fields of papers citing papers by Hervé Tilly
This network shows the impact of papers produced by Hervé Tilly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hervé Tilly. The network helps show where Hervé Tilly may publish in the future.
Co-authors
The 25 scholars most cited alongside Hervé Tilly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 527 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma Hit paper breakdown → | 2002 | 4546 |
| 2 | Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte Hit paper breakdown → | 2010 | 1236 |
| 3 | Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte Hit paper breakdown → | 2005 | 1197 |
| 4 | Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial Hit paper breakdown → | 2010 | 843 |
| 5 | TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis Hit paper breakdown → | 2011 | 776 |
| 6 | Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2015 | 711 |
| 7 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Hit paper breakdown → | 2018 | 554 |
| 8 | Follicular lymphoma international prognostic index. Hit paper breakdown → | 2004 | 551 |
| 9 | 1997 | 518 | |
| 10 | Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial Hit paper breakdown → | 2020 | 460 |
| 11 | Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial Hit paper breakdown → | 2011 | 427 |
| 12 | Treatment of Older Patients with Mantle-Cell Lymphoma Hit paper breakdown → | 2012 | 402 |
| 13 | 1993 | 393 | |
| 14 | 1998 | 382 | |
| 15 | 2008 | 364 | |
| 16 | 2000 | 355 | |
| 17 | Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy Hit paper breakdown → | 2014 | 354 |
| 18 | 2011 | 345 | |
| 19 | 2010 | 324 | |
| 20 | Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma Hit paper breakdown → | 2017 | 312 |
About Hervé Tilly
Hervé Tilly is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Hematology and Neurology, having authored 527 papers that have together received 35.8k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (386 papers), Chronic Lymphocytic Leukemia Research (145 papers), Viral-associated cancers and disorders (77 papers), CNS Lymphoma Diagnosis and Treatment (55 papers), CAR-T cell therapy research (52 papers), Acute Myeloid Leukemia Research (40 papers), Acute Lymphoblastic Leukemia research (34 papers) and Lung Cancer Treatments and Mutations (29 papers). The work is most often cited by research in Pathology and Forensic Medicine (24.8k citations), Genetics (8.9k citations), Oncology (14.7k citations), Neurology (5.6k citations) and Hematology (3.2k citations). Hervé Tilly has collaborated with scholars based in France, United States and Belgium. Frequent co-authors include Bertrand Coiffier, Gilles Salles, Éric Lepage, Christian Gisselbrecht, Philippe Gaulard, Corinne Haïoun, Pierre Lederlin, Raoul Herbrecht, Josette Brière and Éric Van Den Neste. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of Oncology, Hematological Oncology and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.